Cargando…

Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer

PURPOSE: Although adjuvant polychemotherapy improves outcomes for early breast cancer, the significant variability in terms of pharmacokinetics results in differences in efficacy and both short and long-term toxicities. Retrospective studies support the use of dose tailoring according to the hematol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matikas, Alexios, Margolin, Sara, Hellström, Mats, Johansson, Hemming, Bengtsson, Nils-Olof, Karlsson, Lena, Edlund, Per, Karlsson, Per, Lidbrink, Elisabet, Linderholm, Barbro, Lindman, Henrik, Malmstrom, Per, Villman, Kenneth, Foukakis, Theodoros, Bergh, Jonas
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2017
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5838137/ https://www.ncbi.nlm.nih.gov/pubmed/29190004 http://dx.doi.org/10.1007/s10549-017-4599-4

Ejemplares similares

Interplay between copy number alterations and immune profiles in the early breast cancer Scandinavian Breast Group 2004-1 randomized phase II trial: results from a feasibility study
por: Zerdes, Ioannis, et al.
Publicado: (2021)

Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
por: Chrétien, Sebastian, et al.
Publicado: (2019)

The interplay between eosinophils and T cells in breast cancer immunotherapy
por: Zerdes, Ioannis, et al.
Publicado: (2023)

Women with short survival after diagnosis of metastatic breast cancer: a population-based registry study
por: Boman, Caroline, et al.
Publicado: (2022)

Chemotherapy use near the end-of-life in patients with metastatic breast cancer
por: Edman Kessler, Luisa, et al.
Publicado: (2020)

Long-term (up to 16 months) health-related quality of life after adjuvant tailored dose-dense chemotherapy vs. standard three-weekly chemotherapy in women with high-risk early breast cancer
por: Brandberg, Yvonne, et al.
Publicado: (2020)

Immune gene expression and response to chemotherapy in advanced breast cancer
por: Foukakis, Theodoros, et al.
Publicado: (2018)

Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?
por: Matikas, A, et al.
Publicado: (2019)

Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study
por: Kjällquist, Una, et al.
Publicado: (2022)

Expression patterns and prognostic implications of tumor-infiltrating lymphocytes dynamics in early breast cancer patients receiving neoadjuvant therapy: A systematic review and meta-analysis
por: Zhu, Yajing, et al.
Publicado: (2022)

Dissecting Tumor-Immune Microenvironment in Breast Cancer at a Spatial and Multiplex Resolution
por: Tzoras, Evangelos, et al.
Publicado: (2022)

PD-1 protein and gene expression as prognostic factors in early breast cancer
por: Matikas, Alexios, et al.
Publicado: (2020)

Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations
por: Zerdes, Ioannis, et al.
Publicado: (2018)

Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy
por: Niméus-Malmström, Emma, et al.
Publicado: (2008)

Discordance of PD-L1 Expression at the Protein and RNA Levels in Early Breast Cancer
por: Zerdes, Ioannis, et al.
Publicado: (2021)

Programmed death‐ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21‐gene and 70‐gene signatures in estrogen receptor‐positive disease
por: Zerdes, Ioannis, et al.
Publicado: (2020)

Mindfulness and its efficacy for psychological and biological responses in women with breast cancer
por: Kenne Sarenmalm, Elisabeth, et al.
Publicado: (2017)

The NIMO Scandinavian Study: A Prospective Observational Study of Iron Isomaltoside Treatment in Patients with Iron Deficiency
por: Frigstad, Svein Oskar, et al.
Publicado: (2017)

Locally advanced breast cancer()
por: Aebi, Stefan, et al.
Publicado: (2021)

Dynamic evaluation of the immune infiltrate and immune function genes as predictive markers for neoadjuvant chemotherapy in hormone receptor positive, HER2 negative breast cancer
por: Matikas, Alexios, et al.
Publicado: (2018)

Breast cancer hypoxia in relation to prognosis and benefit from radiotherapy after breast-conserving surgery in a large, randomised trial with long-term follow-up
por: Tutzauer, Julia, et al.
Publicado: (2022)

Whole grain foods and health – a Scandinavian perspective
por: Frølich, Wenche, et al.
Publicado: (2013)

Proteomics profiling identify CAPS as a potential predictive marker of tamoxifen resistance in estrogen receptor positive breast cancer
por: Johansson, Henrik J, et al.
Publicado: (2015)

Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast‐conserving surgery: a long‐term follow‐up of the SweBCG91‐RT randomised trial
por: Sjöström, Martin, et al.
Publicado: (2020)

The civic turn of immigrant integration policies in the Scandinavian welfare states
por: Borevi, Karin, et al.
Publicado: (2017)

Prognostic and predictive impact of stroma cells defined by PDGFRb expression in early breast cancer: results from the randomized SweBCG91RT trial
por: Strell, Carina, et al.
Publicado: (2021)

Clinicogenomic Radiotherapy Classifier Predicting the Need for Intensified Locoregional Treatment After Breast-Conserving Surgery for Early-Stage Breast Cancer
por: Sjöström, Martin, et al.
Publicado: (2019)

Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
por: Nordenskjöld, Anna, et al.
Publicado: (2023)

Evidence for Increased Susceptibility to Breast Cancer From Exposure to Ionizing Radiation Due to a Familial History of Breast Cancer: Results From the Swedish Hemangioma Cohort
por: Eidemüller, Markus, et al.
Publicado: (2020)

A ‘civic turn’ in Scandinavian family migration policies? Comparing Denmark, Norway and Sweden
por: Bech, Emily Cochran, et al.
Publicado: (2017)

Gene expression variation to predict 10-year survival in lymph-node-negative breast cancer
por: Karlsson, Elin, et al.
Publicado: (2008)

Use of References in Responses from Scandinavian Drug Information Centres
por: Schjøtt, Jan, et al.
Publicado: (2018)

Identification and validation of single-sample breast cancer radiosensitivity gene expression predictors
por: Sjöström, Martin, et al.
Publicado: (2018)

Preoperative accelerated radiotherapy combined with chemotherapy in a defined cohort of patients with high risk soft tissue sarcoma: a Scandinavian Sarcoma Group study
por: Hall, Kirsten Sundby, et al.
Publicado: (2020)

Integration of biological factors in the treatment plan evaluation in breast cancer radiotherapy
por: Svensson, Henrik, et al.
Publicado: (2019)

The Scandinavian multicenter hemodynamic evaluation of the SJM Regent aortic valve
por: Offstad, Jon, et al.
Publicado: (2011)

Scandinavian Surgical Society: The Oldest International Surgical Society in the World
por: Lindfors, Nina C., et al.
Publicado: (2022)

Does three-dimensional functional infrared imaging improve breast cancer detection based on digital mammography in women with dense breasts?
por: Hellgren, Roxanna J., et al.
Publicado: (2019)

Prognostic role of serum thymidine kinase 1 kinetics during neoadjuvant chemotherapy for early breast cancer
por: Matikas, A., et al.
Publicado: (2021)

An Aesthetic Factor Priority List of the Female Breast in Scandinavian Subjects
por: Sandberg, Lars Johan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k75cddrrk42cc0omhvqvh68fpf